OBJECTIVE: The purpose of this article is to review the data, rationale, and recommendations of vaginal brachytherapy (VBT) in the post-operative treatment of @entity1204 @entity1 . METHODS: The authors performed a thorough review of the medical literature regarding the use of adjuvant VBT in the treatment of @entity1204 . Relevant data are presented in this review. Additionally, personal and institutional practices from the authors are incorporated where relevant. RESULTS: VBT for the adjuvant treatment of early stage @entity1204 @entity1 results in a low rate of recurrence (0-3.1%) with very low rates of @entity137 . PORTEC-2 supports the use of adjuvant VBT versus external beam radiotherapy specifically for high-intermediate risk @entity1204 @entity1 . VBT has low rates of acute and chronic @entity344 and very low rates of second @entity5 . The primary @entity137 of VBT is @entity194 and @entity850 with controversy regarding the use of vaginal dilators for prevention. Data support that @entity1 prefer to be involved in the decision making process for their adjuvant therapy, and @entity1 have a lower minimal desired benefit of adjuvant VBT than do physicians. Guidelines exist from the American Brachytherapy Society and American Society of Radiation Oncology with support from the Society for Gynecologic Oncologists regarding the use of adjuvant VBT. CONCLUSIONS: VBT decreases the risk of recurrence with minimal @entity137 in the adjuvant treatment of @entity1204 . Adjuvant therapy should be discussed in a multi-disciplinary setting with detailed counseling of the risks and benefits with the @entity1 so that she ultimately makes an informed decision regarding her adjuvant therapy.

The role of vaginal cuff brachytherapy in XXXX .

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary malignancy'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal and genitourinary toxicity'] @entity194 :: ('MESH:D001284', 'Disease') :: ['vaginal atrophy'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']
